不同诊断标准对阿尔茨海默病临床研究的影响
研究基于ADNI队列1195名认知正常或受损个体,比较2011 NIA-AA、2016 IWG-2、2018 NIA-AA和2021 IWG-3四种AD诊断标准下的诊断标签分布与预后价值。结果显示42.8%参与者诊断不一致,多发生于单一生物标志物阳性者;除2018 NIA-AA外,各标准均能识别认知障碍风险。
要点
- 四种AD诊断标准下,诊断标签分布不同,AD比例从33.6%至50.0%不等。
- 42.8%参与者诊断不一致,主要见于仅β-淀粉样蛋白或tau阳性个体。
- 除2018 NIA-AA外,其余标准中nAD与irAD组预测认知障碍风险有差异。
核心结论
- 超过42%的研究人群在使用不同AD标准时诊断不一致,主要发生在单一生物标志物阳性个体。
- 除2018 NIA-AA外,所有指南均能识别有认知障碍风险的无症状个体。
- 研究强调指南间重要差异,需更新标准以增强分期指标,并考虑临床、研究、治疗和试验设计方面。
研究设计与样本
- 研究应用临床和生物标志物数据算法,对阿尔茨海默病神经影像学倡议(ADNI)队列中认知正常和认知受损个体进行分类。
- 根据2011 NIA-AA、2016 IWG-2、2018 NIA-AA和2021 IWG-3四种AD诊断指南分配通用诊断标签:非AD(nAD)、AD风险增加(irAD)和AD。
- 共纳入1195名个体,平均年龄73.2±7.2岁,平均教育16.1±2.7年,女性占44.0%。
主要发现
- 2011 NIA-AA标准下nAD=37.8%、irAD=23.0%、AD=39.2%;2016 IWG-2标准下nAD=37.7%、irAD=28.7%、AD=33.6%;2018 NIA-AA标准下nAD=40.7%、irAD=9.3%、AD=50.0%;2021 IWG-3标准下nAD=51.2%、irAD=8.4%、AD=48.3%。
- 512名参与者(42.8%)在所有指南间诊断不一致,其中138例(91.4%)仅β-淀粉样蛋白阳性(CU 65.4%,CI 34.6%),191例(78.6%)仅tau阳性(CU 71.7%,CI 28.3%)。
- nAD与irAD组预测认知障碍的差异:2011 NIA-AA(HR 2.21,95%CI 1.34-3.65,p=0.002)、2016 IWG-2(HR 2.81,95%CI 1.59-4.96,p<0.000)、2021 IWG-3(HR 3.61,95%CI 2.09-6.23,p<0.000),2018 NIA-AA无显著差异(HR 1.69,95%CI 0.87-3.28,p=0.115)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Updates in Alzheimer disease (AD) diagnostic guidelines by the National Institute on Aging-Alzheimer's Association (NIA-AA) and the International Working Group (IWG) over the past 11 years may affect clinical diagnoses. We assessed how these guidelines affect clinical AD diagnosis in a cohort of cognitively unimpaired (CU) and cognitively impaired (CI) individuals. METHODS: We applied clinical and biomarker data in algorithms to classify individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort according to the following diagnostic guidelines for AD: 2011 NIA-AA, 2016 IWG-2, 2018 NIA-AA, and 2021 IWG-3, assigning the following generic diagnostic labels: (1) not AD (nAD), (2) increased risk of developing AD (irAD), and (3) AD. Diagnostic labels were compared according to their frequency, convergence across guidelines, biomarker profiles, and prognostic value. We also evaluated the diagnostic discordance among the criteria. RESULTS: A total of 1,195 individuals (mean age 73.2 ± 7.2 years, mean education 16.1 ± 2.7, 44.0% female) presented different repartitions of diagnostic labels according to the 2011 NIA-AA (nAD = 37.8%, irAD = 23.0%, AD = 39.2%), 2016 IWG-2 (nAD = 37.7%, irAD = 28.7%, AD = 33.6%), 2018 NIA-AA (nAD = 40.7%, irAD = 9.3%, AD = 50.0%), and 2021 IWG-3 (nAD = 51.2%, irAD = 8.4%, AD = 48.3%) frameworks. Discordant diagnoses across all guidelines were found in 512 participants (42.8%) (138 [91.4%] occurring in only β-amyloid [CU 65.4%, CI 34.6%] and 191 [78.6%] in only tau-positive [CU 71.7%, CI 28.3%] individuals). Differences in predicting cognitive impairment between nAD and irAD groups were observed with the 2011 NIA-AA (hazard ratio [HR] 2.21, 95% CI 1.34-3.65, p = 0.002), 2016 IWG-2 (HR 2.81, 95% CI 1.59-4.96, p < 0.000), and 2021 IWG-3 (HR 3.61, 95% CI 2.09-6.23, p < 0.000), but not with 2018 NIA-AA (HR 1.69, 95% CI 0.87-3.28, p = 0.115). DISCUSSION: Over 42% of the studied population presented discordant diagnoses when using the different examined AD criteria, mostly in individuals with a single positive biomarker. Except for 2018 NIA-AA, all guidelines identified asymptomatic individuals at risk of cognitive impairment. Our findings highlight important differences between the guidelines, emphasizing the necessity for updated criteria with enhanced staging metrics, considering clinical, research, therapeutic, and trial design aspects.
引用
- Bieger A, Brum WS, Borelli WV, et al. Influence of Different Diagnostic Criteria on Alzheimer Disease Clinical Research. Neurology. 2024. PMID: 39167736. doi:10.1212/WNL.0000000000209753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。